Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Should You Buy?

Cytokinetics (CYTK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 28, 2026

Baron Health Care Fund Q3 2026 Top Contributors And Detractors

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year organic growth guidance/. MTD's local-currency sales grew 6%, exceeding prior guidance of 3%. TEVA management raised guidance for all three brands.

Seeking Alpha • Oct 26, 2026

Cytokinetics to Announce Third Quarter Results on November 4, 2026

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.

GlobeNewsWire • Oct 21, 2026

Cytokinetics Announces Health Canada Approval of MYQORZO® (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) of New York Heart Association (NYHA) class II-III in adult patients. MYQORZO is a once-daily, oral allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and left ventricular outflow tract (LVOT) obstruction.

GlobeNewsWire • Oct 19, 2026

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 15, 2026 it granted stock options to purchase an aggregate of 60,465 shares of common stock and 40,084 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 29 employees, whose employment commenced in September and October 2026 as a material inducement to their employment.

GlobeNewsWire • Oct 19, 2026

Can Myqorzo's Expansion and Growing Adoption Drive CYTK's Growth?

Cytokinetics' Myqorzo gains commercial traction with growing prescriptions, international launches and promising clinical data that could expand its market opportunity.

Zacks Investment Research • Oct 19, 2026

Cytokinetics Announces Additional Data from ACACIA-HCM Presented at the HFSA Annual Scientific Meeting 2026

Additional Analyses from ACACIA-HCM Further Characterize Exercise Performance, Treatment Effect, Dose Titration and Safety of Aficamten in Non-Obstructive HCM

GlobeNewsWire • Oct 12, 2026

Cytokinetics Announces Four Upcoming Presentations at the HFSA Annual Scientific Meeting 2026

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four upcoming presentations, including two Late Breaking Clinical Research presentations and two oral presentations, at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026 taking place in Phoenix, AZ from October 9 – 12, 2026.

GlobeNewsWire • Oct 2, 2026

Cytokinetics Launches ASPEN-HCM: A Real-World Study Evaluating MYQORZO® (aficamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy

Multi-center Prospective Study to Track Real-World Safety, Clinical Effectiveness, and Healthcare Resource Impact of MYQORZO in Routine Clinical Practice

GlobeNewsWire • Sep 30, 2026

Cytokinetics Maps MYQORZO Expansion, Heart Failure Pipeline at Bernstein Conference

Cytokinetics NASDAQ: CYTK executives outlined the company's commercial expansion plans, cardiovascular pipeline and business-development priorities during a Bernstein investor symposium, highlighting the launch of MYQORZO and clinical programs targeting several forms of heart failure.

MarketBeat • Sep 25, 2026